Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NVE Takes First Shot At Ephedra Ban: FDA Violated DSHEA, Firm Says

This article was originally published in The Tan Sheet

Executive Summary

NVE Pharmaceuticals is challenging FDA's ban of ephedra on the grounds the agency did not meet its burden of proving the ingredient unsafe under the Dietary Supplement Health & Education Act
Advertisement

Related Content

ERSP Refers NVE Pharmaceuticals’ AppuLoss Weight-Loss Ads To FTC
Ephedra lawsuit
FDA Appeals Utah Ephedra Court Ruling, Defends Use Of Risk/Benefit Analysis
Ephedra Ruling Does Not Preclude FDA Legal Action In New District – Lawyers
Ephedra Ban Makes Food, Supplement Regs “Unworkable” – Lawsuit
Ephedra Ban Challengers Face Uphill Battle As Rule Goes Into Effect
Ephedra Ban Effective In April; FDA Will Follow-Up On Internet Firms
FDA Regulatory Framework For Ephedra Ban Expected To Get Court Review
FDA Regulatory Framework For Ephedra Ban Expected To Get Court Review
RAND Report Recommends Case-Control Ephedra Study Look At AE Risk

Topics

Advertisement
UsernamePublicRestriction

Register

PS096589

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel